Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.

IF 2.9 3区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical Drug Investigation Pub Date : 2024-08-01 Epub Date: 2024-07-31 DOI:10.1007/s40261-024-01379-7

Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan-Vidal, Teresa López-Fernández, Ernest Nadal, Delvys Rodríguez-Abreu, María Vares, Úrsula Asensio, Luis F García, Enriqueta Felip

{"title":"Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.","authors":"Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan-Vidal, Teresa López-Fernández, Ernest Nadal, Delvys Rodríguez-Abreu, María Vares, Úrsula Asensio, Luis F García, Enriqueta Felip","doi":"10.1007/s40261-024-01379-7","DOIUrl":null,"url":null,"abstract":"<p><p>The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.</p>","PeriodicalId":10402,"journal":{"name":"Clinical Drug Investigation","volume":" ","pages":"553-576"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11338981/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Drug Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40261-024-01379-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/31 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.

Abstract Image

查看原文本刊更多论文

洛拉替尼（Lorlatinib）治疗ALK+晚期非小细胞肺癌不良事件处理专家共识》。

事实证明，使用无性淋巴瘤激酶（ALK）酪氨酸激酶抑制剂（TKIs）（如lorlatinib）治疗ALK基因重排（或ALK阳性）的非小细胞肺癌（NSCLC）患者，可以改善这些患者的总体生存期和生活质量。然而，洛拉替尼也可能出现不良反应。充分监测和管理这些不良事件对于提高患者对洛拉替尼的依从性至关重要，从而最大限度地提高治疗效果，降低因中断治疗而带来的风险。考虑到劳拉替尼的不良反应可影响不同的器官和系统，因此需要多学科团队的参与，包括心脏病专家、神经科专家、内科专家和肿瘤药剂师。本文基于多学科专家小组的临床经验，介绍了在晚期ALK阳性NSCLC患者中识别和治疗与洛拉替尼相关的最相关不良事件的具体而务实的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Drug Investigation 医学-药学

CiteScore

5.90

自引率

3.10%

发文量

108

审稿时长

6-12 weeks

期刊介绍： Clinical Drug Investigation provides rapid publication of original research covering all phases of clinical drug development and therapeutic use of drugs. The Journal includes: -Clinical trials, outcomes research, clinical pharmacoeconomic studies and pharmacoepidemiology studies with a strong link to optimum prescribing practice for a drug or group of drugs. -Clinical pharmacodynamic and clinical pharmacokinetic studies with a strong link to clinical practice. -Pharmacodynamic and pharmacokinetic studies in healthy volunteers in which significant implications for clinical prescribing are discussed. -Studies focusing on the application of drug delivery technology in healthcare. -Short communications and case study reports that meet the above criteria will also be considered. Additional digital features (including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in Clinical Drug Investigation may be accompanied by plain language summaries to assist readers who have some knowledge, but non in-depth expertise in, the area to understand important medical advances.